Apogee Therapeutics (NASDAQ:APGE) Reaches New 52-Week High – Here’s Why

Shares of Apogee Therapeutics Inc. (NASDAQ:APGE) hit a new 52-week high during mid-day trading on Thursday . The company traded as high as $85.04 and last traded at $78.53, with a volume of 3533056 shares changing hands. The stock had previously closed at $73.00.

More Apogee Therapeutics News

Here are the key news stories impacting Apogee Therapeutics this week:

• Positive Sentiment: Positive 52‑week Phase II Part A results for zumilokibart showing sustained, durable responses and attractive infrequent dosing — data cited as boosting the drug’s commercial promise and near‑term clinical catalysts (Part B 16‑week induction data in Q2; potential Phase 3 in H2 2026). Zacks: APGE Stock Up as Skin Disease Drug Shows Sustained 52-Week Efficacy
• Positive Sentiment: Investor enthusiasm reinforced by buy‑side commentary and bullish coverage calling APGE a “Strong Buy” ahead of upcoming readouts and potential Phase 3 start. Seeking Alpha highlights the program’s extended‑half‑life profile and upcoming catalysts. Seeking Alpha: Strong Buy
• Positive Sentiment: Several firms raised price targets and maintained buy ratings (Citigroup, Canaccord, Guggenheim), increasing upside estimates and supporting near‑term investor optimism. Benzinga: Analyst Coverage TickerReport: Guggenheim Raise
• Neutral Sentiment: Reported short‑interest data appears anomalous (entries showing 0 shares and NaN changes across multiple reports), so there’s no clear short‑pressure signal to explain price moves; treat the short‑interest items as unreliable until clarified.
• Negative Sentiment: Apogee priced an underwritten public offering of 5,000,000 shares at $70.00 (aggregate gross proceeds ~$350M) with a 30‑day option for up to 750,000 additional shares — this raises cash and extends runway but is dilutive and was priced below the current market, which can cap near‑term upside. Closing expected March 26, subject to conditions. GlobeNewswire: Offering Announcement MSN: Offering Coverage

Analyst Ratings Changes

Several research firms have recently issued reports on APGE. Stephens initiated coverage on Apogee Therapeutics in a research report on Tuesday, December 16th. They issued an “overweight” rating and a $95.00 price target on the stock. UBS Group upgraded Apogee Therapeutics to a “strong-buy” rating in a report on Wednesday, January 7th. Royal Bank Of Canada decreased their target price on Apogee Therapeutics from $83.00 to $82.00 and set a “sector perform” rating for the company in a research report on Monday, March 2nd. Jefferies Financial Group reiterated a “buy” rating and issued a $95.00 price target on shares of Apogee Therapeutics in a research report on Monday, February 2nd. Finally, Wolfe Research assumed coverage on shares of Apogee Therapeutics in a report on Wednesday, January 7th. They set a “peer perform” rating for the company. Three equities research analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $110.43.

Apogee Therapeutics Price Performance

The company has a market cap of $5.46 billion, a price-to-earnings ratio of -18.61 and a beta of 1.39. The stock has a 50-day moving average price of $71.09 and a 200 day moving average price of $64.05.

Apogee Therapeutics (NASDAQ:APGE) last issued its quarterly earnings data on Monday, March 2nd. The company reported ($1.03) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.05) by $0.02. Sell-side analysts expect that Apogee Therapeutics Inc. will post -3.09 EPS for the current fiscal year.

Insider Buying and Selling

In related news, CEO Michael Thomas Henderson sold 20,000 shares of the business’s stock in a transaction on Wednesday, March 11th. The shares were sold at an average price of $74.78, for a total value of $1,495,600.00. Following the sale, the chief executive officer directly owned 1,152,987 shares of the company’s stock, valued at approximately $86,220,367.86. The trade was a 1.71% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider Carl Dambkowski sold 5,500 shares of the stock in a transaction dated Wednesday, March 4th. The stock was sold at an average price of $71.06, for a total value of $390,830.00. Following the transaction, the insider owned 209,773 shares of the company’s stock, valued at approximately $14,906,469.38. This trade represents a 2.55% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 1,839,700 shares of company stock worth $140,118,083 over the last ninety days. Company insiders own 42.77% of the company’s stock.

Hedge Funds Weigh In On Apogee Therapeutics

A number of large investors have recently bought and sold shares of APGE. Rockefeller Capital Management L.P. acquired a new stake in shares of Apogee Therapeutics in the fourth quarter valued at approximately $25,000. ANTIPODES PARTNERS Ltd grew its position in Apogee Therapeutics by 41.2% in the third quarter. ANTIPODES PARTNERS Ltd now owns 843 shares of the company’s stock valued at $33,000 after purchasing an additional 246 shares in the last quarter. Los Angeles Capital Management LLC acquired a new stake in Apogee Therapeutics in the 4th quarter valued at $37,000. Quantbot Technologies LP bought a new stake in Apogee Therapeutics during the 3rd quarter worth about $96,000. Finally, Seven Fleet Capital Management LP acquired a new position in shares of Apogee Therapeutics during the 4th quarter worth about $136,000. Institutional investors and hedge funds own 79.04% of the company’s stock.

About Apogee Therapeutics

Apogee Therapeutics, Inc is a clinical-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics that selectively target the nuclear receptor RORγt, a master regulator of T cell-driven inflammatory pathways. By modulating RORγt activity, Apogee aims to offer an oral treatment option for patients with autoimmune and inflammatory skin disorders.

The company’s lead candidate, APG-157, is an oral RORγt inverse agonist currently undergoing early-stage clinical evaluation for moderate to severe plaque psoriasis.